VIICTR
Profiles
ORIT
Pediatrics CRA
Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Additive effect of TAK-491, a new angiotensin receptor blocker, and pioglitazone, in reducing myocardial infarct size.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Additive effect of TAK-491, a new angiotensin receptor blocker, and pioglitazone, in reducing myocardial infarct size.
Additive effect of TAK-491, a new angiotensin receptor blocker, and pioglitazone, in reducing myocardial infarct size. Cardiovasc Drugs Ther. 2010 Apr; 24(2):107-20.
View in:
PubMed
subject areas
Angiotensin II Type 1 Receptor Blockers
Animals
Apoptosis
bcl-2-Associated X Protein
Blood Pressure
Cyclooxygenase 1
Cyclooxygenase 2
Drug Therapy, Combination
Heart Rate
Heart Ventricles
Hypoglycemic Agents
Male
Membrane Proteins
Mitogen-Activated Protein Kinase 1
Mitogen-Activated Protein Kinase 3
Myocardial Infarction
Myocardial Reperfusion Injury
Nitric Oxide Synthase Type I
Nitric Oxide Synthase Type II
Nitric Oxide Synthase Type III
p38 Mitogen-Activated Protein Kinases
Phosphorylation
Proto-Oncogene Proteins c-akt
Rats
Rats, Sprague-Dawley
Thiazolidinediones
Ventricular Function, Left
authors with profiles
YOCHAI BIRNBAUM